Biotech Values

[genisi]

Do you recall GILD releasing SVR4 rates for either the POSITRON or FISSION studies?

I only remember SVR4 data for the ELECTRON study and AI444040 Study (the sofo+dacla trial) at AASLD.
As for the POSITRON trial, there's this paragraph in the PR:

All patients receiving sofosbuvir/RBV became HCV RNA negative on treatment and relapse accounted for all virologic failures.

http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=1761988&highlight=

This implies that the reason for relapsing is not resistance as there was no virologic breakthrough
on-treatment and sequencing from erlier trials didn't identify any S282T-containing mutants in relapsers.
I think that with interferon-free regimens clearing the virus is the problem and focus is more on possible late relapse as seen in ABT’s PILOT trial and in BI’s SOUND-C2 trial.